#GoingGlobal: VSU boosts drug discovery, development with leading China pharma

The future of health biotechnology is here. 

During its 102nd Founding Anniversary, Visayas State University (VSU) did more than honor a century of excellence in agriculture and natural resources, as it closed a strategic partnership with Overseas Pharmaceuticals Ltd. (OPL), a leading pharmaceutical company based in Guangzhou, China signaling its intent to evolve from an agricultural stronghold to a future hub for drug discovery, a vision now taking shape as a “Pharmazone.”

The historic signing, one of the highlights of AbanTeknolohiya 3.0 on April 15, 2026, was witnessed by Dr. Huaihan Cai, Vice President for International Business Development at OPL, Dr. Prose Ivy G. Yepes, VSU President, Dr. Santiago T. Peña Jr., Vice President for Research, Extension, and Innovation, Dr. Lotis M. Balala, Director of the Advanced Research and Innovation Center (ARIC), Dr. Marciana B. Galambao, Head, Department of Biotechnology (BioTech), and Mr. Lourd Franz Gabunada, Director of Eastern Visayas Biotechnology Research Center (EV Biotech).

At the core of the agreement is a dynamic exchange of knowledge, talent, and resources, geared towards pharmaceutical innovation. 

OPL, for its part, takes on a great role in bringing global industry experience directly into the university. Through the deployment of senior experts as visiting professors and lecturers, the company actively contributes to curriculum enhancement, mentoring, and thesis development. 

This ensures that students are not only grounded in theory but are also exposed to real-world pharmaceutical practices.

Beyond the classroom, OPL opens its doors to VSU researchers and students through training and immersion opportunities in its advanced research and development facilities in Guangzhou, China. 

These engagements allow Filipino scientists to gain firsthand experience in drug research and development, clinical trial support, and data-driven pharmaceutical innovation.

Complementing this is OPL’s commitment to resource sharing, granting VSU faculty access to cutting-edge laboratories and technologies, an essential step toward fostering collaborative breakthroughs in drug discovery.

Furthermore, VSU anchors this partnership by cultivating the next generation of scientists and innovators. Through its Department of Biotechnology, ARIC,  and EV-Biotech, the university provides the intellectual capital and research environment necessary to drive joint initiatives.

VSU also plays a unique role as a cultural and academic bridge, facilitating exchanges that go beyond science. By supporting language and cultural engagement between Filipino and Chinese experts, the partnership ensures a deeper, more cohesive collaboration.

Guided by the leadership of University President Dr. Prose Ivy G. Yepes in coordination with the pillars of biotechnology, the university is steering its efforts toward a critical goal: translating research into real-world pharmaceutical solutions.

From agreement to action: Setting the tone

The significance of the partnership was immediately realized through the International Seminar on Pharmaceuticals and Drug Development on April 21, 2026.

The seminar gathered a diverse group of experts, each contributing a vital piece to the complex puzzle of modern drug development, from discovery and technology to industry application and global positioning. 

At the forefront was keynote speaker Dr. Huaihan Cai, Vice President for International Business Development at OPL.

In his talk on the China Biopharmaceutical Revolution, he presented a compelling narrative of transformation on how China evolved from a manufacturing hub into a global leader in pharmaceutical innovation.

His message resonated deeply. “Drug development is not just about scientific discovery, it is about building systems, forging partnerships, and navigating global pathways,” he stressed.

For VSU, this was more than insight; it was a roadmap.

Science at the Speed of Innovation

Complementing the global perspective was Mark Ryan Tripole, Faculty of the Department of Pure and Applied Chemistry (DoPAC), who introduced participants to the rapidly evolving field of In Silico drug discovery.

Through a multi-layered systems approach, integrating network pharmacology, molecular docking, and molecular dynamics, he demonstrated how researchers can simulate and analyze molecular interactions digitally. 

This approach not only accelerates drug discovery but also opens new possibilities for exploring both Traditional Chinese Medicine and Philippine biodiversity as viable sources of therapeutic compounds.

Grounding the discussion in the local context, Ms. Jo Jane Atok-Abulencia, VSU Faculty Researcher, highlighted the work of the Tuklas Lunas Development Center, emphasizing the country’s rich biological resources and their untapped potential in pharmaceutical development.

Adding the industry lens, Mr. Phil Aidan Cruz of Herbanext Laboratories Inc., outlined the realities of the Philippine pharmaceutical landscape, its challenges, gaps, and opportunities for growth.

This lecture on drug development and medical discovery was made possible through the efforts of Dr. Ea Kristine Clarisse T. Escueta together with her colleagues in the Advanced Research Innovation Center, EV Biotechnology Research Center, Department of Biotechnology, in collaboration with the Department of Development Communication and the Visayas Consortium for Agriculture, Aquatic, and Natural Resources Program.

Toward a Future “Pharmazone”

Together, the voices at the seminar painted a complete picture of the pharmaceutical industry, from discovery and validation to commercialization and global distribution.

More importantly, they reinforced a shared vision: That VSU has moved beyond and has evolved from its agricultural legacy.

The partnership with OPL, set to unfold over the next three years, represents a strategic leap toward positioning the Philippines as a player in global pharmaceutical innovation.

As VSU celebrates 102 years of service and excellence, one thing is clear: It is no longer just growing crops; it is growing cures, building connections, and shaping the future of Filipino health care, one discovery at a time.

This article is aligned with the Sustainable Development Goal (SDG) 3: Good Health and Well-Being (SDG)8: Decent Work and Economic Growth; 9: Industry, Innovation, and Infrastructure; SDG 11: Sustainable Cities and Communities; and; SDG 17: Partnerships for the Goals.

• Next